Journal
CLINICAL IMMUNOLOGY
Volume 238, Issue -, Pages -Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.clim.2022.109024
Keywords
Myeloid-derived suppressor cell; SARS-CoV-2; COVID-19; Immunopathology
Categories
Funding
- Committee of Science of the Ministry of Education and Science of the Republic of Kazakhstan [AP09259390, AP09259103]
Ask authors/readers for more resources
This article reviews the current findings on myeloid-derived suppressor cells (MDSCs) in COVID-19 and discusses the complex role of these cells in the immunopathology of the disease.
Coronavirus disease 2019 (COVID-19) is a potentially life-threatening infection characterized by excessive inflammation, coagulation disorders and organ damage. A dysregulated myeloid cell compartment is one of the most striking immunopathologic signatures of this newly emerged infection. A growing number of studies are reporting on the expansion of myeloid cells with immunoregulatory activities in the periphery and airways of COVID-19 patients. These cells share phenotypic and functional similarities with myeloid-derived suppressor cells (MDSCs), which were first described in cancer patients. MDSCs are a heterogeneous population of pathologically activated myeloid cells that exert immunosuppressive activities against mainly effector T cells. The increased frequency of these cells in COVID-19 patients suggests that they are involved in immune regulation during this infection. In this article, we review the current findings on MDSCs in COVID-19 and discuss the complex role of these cells in the immunopathology of COVID-19.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available